

1  
2  
3 **Undiagnosed and untreated chronic kidney disease and its impact on renal**  
4  
5 **outcomes in the Japanese middle-aged general population**  
6  
7  
8  
9

10 Yukari Yamada<sup>1,2,3</sup>, Tatsuyoshi Ikenoue<sup>1</sup>, Yoshiyuki Saito<sup>1</sup>, Shingo Fukuma<sup>1</sup>  
11  
12  
13

14 <sup>1</sup>Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan  
15  
16

17 <sup>2</sup>Centre for Medical Education and Internationalization, Kyoto University Graduate  
18  
19 School of Medicine, Kyoto, Japan  
20

21 <sup>3</sup>Centre for Research Excellence, Faculty of Health Sciences, Palacky University,  
22  
23 Olomouc, Czech Republic  
24  
25

26  
27  
28 Correspondence to: Shingo Fukuma  
29

30 Human Health Sciences, Kyoto University Graduate School of Medicine  
31  
32

33 53 Shogoin-Kawahara, Sakyo, Kyoto 606-8507, Japan  
34

35 Tel +81-75-751-3925  
36

37 Fax +81-75-751-3909  
38

39 Email [fukuma.shingo.3m@kyoto-u.ac.jp](mailto:fukuma.shingo.3m@kyoto-u.ac.jp)  
40  
41  
42  
43

44 Word count: 2856 (From Introduction to Discussion excluding tables)  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Background:** The effectiveness of identifying and monitoring early-stage chronic kidney disease (CKD) is not fully recognised. This study quantified people with undiagnosed CKD among the middle-aged Japanese population and clarified potential risks of untreated CKD.

**Methods:** We included 71,233 individuals who underwent annual health check-ups (AHCs) in 2014 for both baseline and follow-up proteinuria and serum creatine measurements. CKD was identified by AHC data as proteinuria or estimated glomerular filtration rate (eGFR)  $<60$  ml/min/1.73 m<sup>2</sup>. We differentiated undiagnosed from diagnosed CKD using the medical claims database. In undiagnosed CKD, we assessed risk differences for disease progression, defined as an eGFR decline slope  $>3$  ml/min/1.73 m<sup>2</sup>/year or proteinuria incidence over three years, between those who visited a physician for CKD treatment within 6 months after AHC and those who did not.

**Results:** CKD prevalence was 5.7% (5.2% undiagnosed and 0.5% diagnosed). Only 2.1% of the undiagnosed CKD patients visited a physician for CKD treatment within 6 months after AHC. Between-group risk differences in instrumental variable adjustment models showed that those left untreated progressed to kidney diseases 16.3% more often than those who visited physicians for CKD treatment.

**Conclusion:** CKD was undiagnosed in 5.2% of the middle-aged general population. Only a few people visited physicians for CKD treatment. Visiting physicians for CKD treatment during the first 6 months after screening may be associated with a lower risk of kidney disease progression.

1  
2  
3 **Keywords:** population prevalence, early identified CKD, annual screening, instrumental  
4  
5 variable analysis  
6  
7  
8  
9

10 **What is already known on this subject.**

- 12 • Chronic kidney disease (CKD) is a condition characterized by a gradual loss of kidney function.
- 14 • Early identification and treatment of this disease are recommended, but the effectiveness of this  
15 practice has been controversial.

17 **What this study adds.**

- 18 • We compared the disease outcome over three years between those who visited a physician after  
19 the screening for CKD and those who did not.
  - 20 • Visiting a physician after the screening for CKD was associated with a lower risk of kidney disease  
21 progression.
  - 22 • This finding may support an importance of ensuring a link between the positive results of renal  
23 screening and medical management.
- 24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Chronic kidney disease (CKD) is a global health issue, affecting approximately 11–13% of the population across countries.[1-3] It has serious consequences on the quality of life, as well as on social cost when it comes to end-stage renal disease (ESRD).[4, 5] The number of patients with CKD is projected to further increase due to the aging population and increased prevalence of non-communicable diseases, such as diabetes and hypertension.[6]

Given the asymptomatic nature of early-stage CKD and effective strategies to prevent or delay CKD progression through lifestyle modifications, public health measures to detect CKD using simple laboratory tests have been recommended.[7, 8] However, the effectiveness of identifying and monitoring early-stage CKD in primary care has not been fully recognised among physicians expressing concerns about the accuracy of diagnostic tests and overmedicalization of normality.[9, 10] Moreover, the cost-effectiveness of these activities in the general population has been questioned in several studies.[11-13] For example, a study using a cohort of simulated patients from age 50 to 90 years or death found that microalbuminuria screening followed by treatment with blood pressure lowering medications was not cost-effective for patients without diabetes and hypertension, unless they were conducted as part of existing physician visits.[11] However, we are unaware of the prevalence of undiagnosed CKD in the general population, nor how protective medical treatment may be against CKD progression followed by the identification of undiagnosed CKD in the real world.

1  
2  
3 This study, therefore, aimed to first quantify undiagnosed CKD detected through an  
4 annual health check-up (AHC) program among the middle-aged general population in  
5 Japan and to second clarify if the medical treatment they received was protective against  
6 CKD progression.  
7  
8  
9  
10  
11  
12

## 13 **MATERIALS AND METHODS**

### 14 **Data source**

15  
16  
17 Preventable non-communicable diseases, such as diabetes and hypertension, are assumed  
18 to be the underlying causes for emerging long-term care needs. In an effort to screen for  
19 preventable non-communicable diseases, all social health insurers in Japan have been  
20 required to conduct an AHC for their insureds, aged between 40 and 74 years, since  
21 2008.[14] The examinees were informed individually about the results after the AHC  
22 with medical summary and recommendations for healthy behaviors, including visiting a  
23 physician, were indicated as necessary. We obtained the AHC data generated between  
24 2011 and 2017 from the Health Insurance Association for Architecture and Civil  
25 Engineering companies (HIA<sup>2</sup>CE), one of the largest social health insurers that covers  
26 over 1800 enterprises throughout Japan, with 180,000 workers in architecture and  
27 engineering and their family members. The AHC data include self-reported lifestyle and  
28 history of diseases, measurements of abdominal circumference and blood pressure, and  
29 laboratory test results of urine and blood.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 To obtain information on physician visits for CKD treatment, we linked the AHC data  
52 with the database of insurance claims, which contains a sequential history of each insured  
53 person's encounter with the healthcare system and diagnoses since September 2013. The  
54  
55  
56  
57

linkage was made while maintaining confidentiality by hash variables generated from identifiers. Further, we obtained information on the numbers of insured people of each enterprise.

### Study population

This study included people who underwent an AHC covered by HIA<sup>2</sup>CE with proteinuria and serum creatine measurements in the 2014 fiscal year (FY), which is from April 2014 to March 2015 (n=82,932). We further excluded people who had less than two serum creatinine values between FY2015 and FY2017 (n=11,699), resulting in 71,233 AHC examinees in FY2014 with outcome of interests.

CKD was defined by either decreased GFR or kidney damage, as recommended in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines[15]. Decreased GFR was defined as  $GFR < 60 \text{ ml/min/1.73 m}^2$  estimated using the Japanese coefficient-modified CKD Epidemiology Collaboration equation for GFR [16, 17] based on serum creatine. Kidney damage was defined as proteinuria  $\geq 1+$  using reagent strip urinalysis for total protein with manual reading, which corresponds approximately to urine albumin-to-creatinine ratio  $\geq 30 \text{ mg/g}$ .

Among those who were screened as CKD (n=4,053), we differentiated *undiagnosed* CKD from *diagnosed* CKD. The *diagnosed* CKD was defined as end-stage renal disease (self-report at AHC, n=91) or as being under CKD treatment before AHC (n=261). The CKD treatment before AHC was identified by linking the AHC data with medical claims as an absence of physician visits for CKD treatment for three months before the month of the indexed AHC, which could vary from January 2014 to March 2015. CKD treatment was

1  
2  
3 defined as an outpatient physician visit for CKD-related diagnoses, the coding of which is  
4 required for reimbursements from payers in Japan, in medical claims shown in  
5  
6  
7  
8 Supplementary Table 1. The selection process of the study participants is shown in  
9  
10  
11  
12  
13 Supplementary Figure 1.

### 14 **Outcome: Progression of kidney disease over three years**

15  
16  
17 Outcome of medical treatment was defined as a progression of kidney disease over three  
18  
19 years (i.e., FY2014-FY2017). It was defined as a composite variable consisting of an  
20  
21 eGFR decline slope greater than 3 ml/min /1.73 m<sup>2</sup>/year or an incidence of proteinuria  
22  
23 among those with negative baseline proteinuria over three years. The eGFR decline slope  
24  
25 was determined as an annual change estimated using an ordinary least-square regression  
26  
27 model with all available eGFR measurements obtained during the three years; 63,561  
28  
29 participants were included in the calculation.  
30  
31  
32

### 33 **Exposure variable: CKD medical treatment**

34  
35  
36  
37 Individual variations in the timing to visit a physician for CKD medical treatment after  
38  
39 the indexed AHC was also identified by linking the AHC data with the medical claims.  
40  
41  
42 We defined our exposure variable as a physician visit for CKD-related diagnosis that  
43  
44 occurred within 6 months after the AHC.  
45  
46

### 47 **Covariates**

48  
49  
50 To adjust for confounders, patient characteristics (age [numeric] and gender), eGFR  
51  
52 (numeric), urine protein (-, ±, +, ++, +++, +++++), body mass index (numeric), smoking  
53  
54 (binary), and comorbidities (diabetes, hypertension, history of stroke or cardiovascular  
55  
56  
57

1  
2  
3 disease) at baseline were included as covariates. We defined diabetes as having  
4  
5 hemoglobin A1c (HbA1c) level of 6.5% or higher or use of glucose-lowering drugs (self-  
6  
7 reported) and hypertension as having systolic blood pressure/diastolic blood pressure  
8  
9  $\geq 140/90$  or use of blood pressure-lowering drugs (self-reported).  
10  
11

### 12 13 **Instrumental variables**

14  
15  
16 Although observational studies have great potential for real-world comparisons of  
17  
18 treatment effect and long-term outcomes, they have a variety of analytical challenges,  
19  
20 such as confounding and bias, that result from differences in prognostic correlates  
21  
22 between comparison groups of interest.[18] To minimise the impact of the limitations, we  
23  
24 used instrumental variable (IV) analyses when assessing the association between the  
25  
26 exposure variable (visiting a physician for CKD medical treatment after AHC) and the  
27  
28 outcome (progression of kidney disease over three years). The likelihood of visiting a  
29  
30 physician after screening is considered to be influenced by the occupational environment  
31  
32 because it usually requires taking a day off from work.[19] With an assumption that these  
33  
34 enterprise-level variables are likely to be unrelated to unmeasured confounders, we used  
35  
36 two enterprise-level variables as IVs in the main analyses: the size of the enterprise and  
37  
38 the proportion of ACH receivers per enterprise. To assess the IV assumptions, we  
39  
40 reported baseline characteristics according to the instruments to estimate correlations  
41  
42 between the exposure and the instrument variables (Supplementary Tables 2 and 3) and  
43  
44 Montiel-Pflueger robust weak instrument tests.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Statistical analysis

We initially described the prevalence of *undiagnosed* CKD and their characteristics to compare with non-CKD and *diagnosed* CKD in our study sample. Among the *undiagnosed* CKD, we drew a Kaplan-Meier plot of time to visit a physician after the AHC for 12 months. To compare those left untreated with those treated within 6 months among the *undiagnosed* CKD, predictive margins from logistic regressions were used to calculate age- and sex-adjusted prevalence ratios for risk factors. To assess associations of visiting a physician for CKD treatment after the AHC with the progression of kidney diseases over three years, a multivariable logistic model with adjustment for potential confounders was used. In the IV analysis, a two-stage residual inclusion approach was applied.[20] In the first stage, we used a logistic regression model with our exposure variable as a dependent variable, and the enterprise-level Ivs and measured confounders as independent variables. Using the first-stage model, we estimated the residual for each person. In the second stage, we applied a logistic model with the progression of kidney disease as a dependent variable, and the exposure variable, residual from the first-stage model, and measured confounders as independent variables. We computed estimates of the adjusted risk differences with delta-method standard errors for each exposure category.[21]

### Sensitivity analysis

We performed three sensitivity analyses. First, CKD definition was redefined as CKD confirmed both in 2013 AHC and 2014 AHC. This analysis reduced the analytic sample to 1,181. Second, since the amount of eGFR reduction rate that is clinically important varies among studies, we carried out a sensitivity analysis with eGFR slope decline

1  
2  
3 alternatively defined as greater than 5 ml/min/1.73 m<sup>2</sup>/year. Third, we used another  
4  
5 enterprise-level IV to capture how much more or less than expected people visit a  
6  
7 physician in their working place on average in the 3 months before AHC, the methods of  
8  
9 which were used in a clinical epidemiological study to assess a selection of psychological  
10  
11 therapy.[22] For this IV, we calculated the ratios for each enterprise and for each month  
12  
13 between the observed number of CKD medical treatment and the expected numbers that  
14  
15 were predicted from a logistic regression model, including gender, age, and morbidity  
16  
17 (diabetes mellitus, hypertension, history of stroke, and cardiovascular disease) of the  
18  
19 entire AHC examinees. Baseline characteristics according to quintiles of the instrument  
20  
21 are reported in Supplementary Table 4. All analyses were performed using Stata, version  
22  
23 15.1 (StataCorp®, College Station, TX, USA). All tests were 2-sided with p-values <0.05  
24  
25 considered statistically significant.  
26  
27  
28  
29

### 30 31 **Institutional review board approval**

32  
33 The Institutional Review Board (IRB) of Kyoto University approved the study (R0817).  
34  
35 We analyzed the data anonymously, and the IRB waived informed and signed consent for  
36  
37 this observational study from each participant. This research was conducted in  
38  
39 accordance with the principles embodied in the Declaration of Helsinki.  
40  
41  
42  
43

### 44 45 **RESULTS**

46  
47 The prevalence of CKD screened in 2014 AHC was 5.68% (95% confidence interval  
48  
49 [CI], 5.52 to 5.86), with 5.19% *undiagnosed* CKD (95% CI, 5.03 to 5.36) and 0.49%  
50  
51 *diagnosed* CKD (95% CI, 0.44 to 0.54). Table 1 describes the characteristics of those  
52  
53 without CKD (n=67,180), those with *undiagnosed* CKD (n=3,701), and those with  
54  
55  
56  
57

1  
2  
3 *diagnosed* CKD (n=352). People with CKD were older, more obese and had more  
4 comorbid conditions compared with those without CKD. No notable differences were  
5 found in the demographics and comorbid conditions between *undiagnosed* and *diagnosed*  
6 CKD, except more people with *diagnosed* CKD were under medication and had history  
7 of diseases. Either an eGFR decline defined as 3 ml/min/1.73 m<sup>2</sup>/year or greater or an  
8 incidence of proteinuria over three years was observed in over 30% of those with  
9 *diagnosed* CKD, while it was 15% among those with *undiagnosed* CKD.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 **Table 1** Participant characteristics by CKD and status of diagnosis  
21

Characteristics	No CKD	CKD	
	n=67,180	Undiagnosed	Diagnosed
		n=3,701	n=352
Age group, %			
40–49	50.2	35.9	32.9
50–59	33.4	33.8	34.9
≥60	16.4	30.3	32.4
Age mean (SD)	50.6 (7.6)	53.7 (8.5)	54.2 (8.1)
Male, %	74.1	88.0	91.2
BMI group, %			
<23.0	44.8	26.6	22.4
23.0–27.4	42.1	47.2	46.6
≥27.5	13.2	26.2	31.0

BMI mean (SD)	23.7 (3.6)	25.4 (4.2)	25.8 (4.1)
Systolic blood pressure			
≥140 mmHg, %	15.7	27.0	27.8
SBP mean (SD)	124.3 (16.7)	130.8 (19.0)	130.9 (18.9)
Diastolic blood pressure			
≥90 mmHg, %	14.2	24.8	19.0
DBP mean (SD)	77.2 (11.2)	82.0 (12.7)	79.9 (11.7)
HbA1c			
≥6.5%, %	5.8	16.7	32.4
HbA1c mean (SD)	5.58 (0.64)	5.93 (1.10)	6.28 (1.29)
eGFR group, %			
≥90	18.4	10.6	5.4
60–89	81.6	50.4	22.2
45–59	0.0	39.0	72.4
eGFR mean (SD)	83.1 (7.8)	71.1 (15.9)	48.8 (24.9)
Antihypertensive drugs, %	14.2	34.1	76.1
Anti-diabetic drugs, %	4.1	11.7	37.5
Anti-hyperlipidaemic drugs, %	8.8	18.6	37.8
History of cardiovascular disease/stroke, %	2.9	6.2	13.4

Smoking, %	29.3	32.5	25.3
Progression of renal disease, %			
Composite outcome	12.1	15.0	31.8
eGFR slope decline <sup>a</sup>	9.1	13.5	27.9
Proteinuria incidence <sup>b</sup>	5.5	9.0	26.0

**Notes:** <sup>a</sup> eGFR decline was defined as 3 ml/min/1.73 m<sup>2</sup>/year or a greater decrease described by the individual participant slope of eGFR during the 3-year follow-up.

<sup>b</sup> Excluded participants with proteinuria at baseline. n=58,217 for non-CKD, 1,150 for undiagnosed CKD, 102 for diagnosed CKD

**Abbreviations:** CKD, chronic kidney disease; BMI, body mass index; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate

The prevalence of medical treatment provided after the indexed AHC among those with *undiagnosed* CKD is described in Figure 1. Only 2.13% (95% CI, 1.69 to 2.65) of them visited a physician seeking CKD treatment within 6 months after AHC. The prevalence slightly increased to 3.57% (95% CI, 2.99 to 4.21) within 12 months.

Table 2 shows age- and sex-adjusted prevalence ratios for risk factors for left untreated CKD among those with *undiagnosed* CKD. The risk factors were almost identically distributed between left untreated and treated CKD.

**Table 2** Age- and sex-adjusted prevalence ratios for risk factors for left untreated CKD (n=3,701)

Characteristics	Crude prevalence, %	Prevalence ratio (95% CI)
Age		
40–49	98.32	1.00 (reference)
50–59	97.57	0.99 (0.98–1.00)
≥60	97.57	0.99 (0.98–1.00)
Female		
Male	98.20	1.00 (reference)
Male		
	97.82	1.00 (0.98–1.01)
BMI		
<22.9	97.87	1.00 (reference)
23–27.4	98.22	1.01 (0.99–1.02)
≥27.5	97.22	0.99 (0.98–1.01)
Systolic blood pressure		
<140 mmHg	98.04	1.00 (reference)
≥140 mmHg	97.40	0.99 (0.98–1.01)
Diastolic blood pressure		
<90 mmHg	98.06	1.00 (reference)
≥90 mmHg	97.28	0.99 (0.98–1.00)
HbA1c		
<6.5%	98.40	1.00 (reference)
≥6.5%	95.61	0.97 (0.95–0.99)
Antihypertensive drugs		
No	98.23	1.00 (reference)

Yes	97.23	0.99 (0.98–1.00)
Anti-diabetic drugs		
No	98.32	1.00 (reference)
Yes	94.46	0.96 (0.94–0.98)
Anti-hyperlipidemic drugs		
No	98.04	1.00 (reference)
Yes	97.10	0.99 (0.98–1.01)
History of cardiovascular		
disease/stroke	97.81	1.00 (reference)
No	98.69	1.01 (1.00–1.03)
Yes		
Smoking		
No	98.16	1.00 (reference)
Yes	97.25	0.99 (0.98–1.00)

**Abbreviations:** CI, confidence interval; CKD, chronic kidney disease; BMI, body mass index; HbA1c, hemoglobin A1c

Progression of kidney disease was observed in 20.3% (n=16/79, 95% CI, 12.0 to 30.8) of those being treated and in 14.9% (n=539/3,622, 95% CI, 13.7 to 16.1) of those left untreated. Between-group risk differences for the progression of kidney disease were not observed in both age- and sex-adjusted models and multivariate-adjusted models.

However, the IV-adjusted models showed that those left untreated were more likely to

progress to kidney disease (Table 3). The results were similar when each outcome was evaluated separately.

**Table 3** Associations between medical treatment and progression of renal disease among people with undiagnosed CKD

Outcome	Treated within		Left untreated		Between group differences <sup>a</sup>			
	6 months n=79		n=3,622		Age- and sex- adjusted	Adjusted <sup>b</sup>	IV adjusted <sup>c</sup>	F
	n	Proportion (95% CI)	n	Proportion (95% CI)	RD <sup>†</sup> (95% CI)	RD <sup>†</sup> (95% CI)	RD <sup>†</sup> (95% CI)	
Composite outcome	16	20.3 (12.0 to 30.8)	539	14.9 (13.7 to 16.1)	-5.01 (- 13.78 to 3.77)	1.80 (- 4.57 to 8.17)	16.31 (15.19 to 17.43)	2.944
eGFR slope decline <sup>d</sup>	14	18.2 (10.3 to 28.6)	448	13.3 (12.2 to 14.5)	-4.49 (- 13.02 to 4.05)	1.56 (- 4.60 to 7.71)	14.92 (13.81.to 16.02)	2.884
Proteinuria incidence <sup>e</sup>	2	10.0 (1.2 to 31.7)	101	8.9 (7.3 to 10.8)	-0.52 (- 13.10 to 12.06)	1.71 (- 7.96 to 11.38)	10.39 (8.79 to 11.99)	1.634



1  
2  
3 **Notes:** <sup>a</sup> Risk differences were estimated from logistic regression models with the  
4 progression of kidney disease as a dependent variable with treated within 6 months as a  
5 reference. Positive values indicate a higher probability of progression of kidney disease  
6 for people left untreated.  
7  
8  
9

10  
11  
12 <sup>b</sup> Adjusted for gender, age (numeric), baseline eGFR (numeric), baseline proteinuria  
13 (binary), baseline body mass index (numeric), baseline diabetes mellitus (binary),  
14 baseline hypertension (binary), baseline smoking status (binary), history of stroke  
15 (binary), and history of cardiovascular disease (binary).  
16  
17  
18

19  
20  
21 <sup>c</sup> Instrumental variable analysis via a two-stage residual inclusion approach using  
22 enterprise-level variables as instruments. Weak instrument was tested using the Montiel-  
23 Pflueger robust weak instrument test (confidence level  $\alpha=0.05$ ) with effective F  
24 statistics.  
25  
26  
27  
28  
29

30  
31 <sup>d</sup> eGFR decline was defined as  $3 \text{ ml/min/1.73 m}^2/\text{year}$  or a greater decrease described by  
32 the individual participant slope of eGFR during the 3-year follow-up.  
33  
34

35  
36 <sup>e</sup> Excluded participants with proteinuria at baseline ( $n=1,427$ ), participants treated within  
37 6 months ( $n=22$ ), and participants left untreated ( $n=1,130$ )  
38  
39

40 **Abbreviations:** CKD, chronic kidney disease; RD, risk difference; CI, confidence  
41 interval; IV, instrumental variable; eGFR, estimated glomerular filtration rate  
42  
43  
44

45  
46  
47 Sensitivity analyses with restricted samples of those with CKD were confirmed through  
48 two consecutive AHCs (i.e., 2013 and 2014), with an alternative outcome definition as 5  
49  $\text{ml/min/1.73 m}^2$  or greater of eGFR slope annual decline, and with an alternative IV  
50 showed almost identical results to the main findings (Supplementary Table 5).  
51  
52  
53  
54  
55  
56  
57

## DISCUSSION

This study shows that undiagnosed CKD was screened in 5.2% of the middle-aged population and only a few of those with undiagnosed CKD visited a physician for CKD treatment within 6 months (2.1%) and 12 months (3.6%) after the screening. The average effect of medical treatment among the subgroup of participants for whom their work place determines its health seeking behaviour indicates that people with undiagnosed CKD had a lower risk of progressing kidney disease if they visited a physician for CKD treatment during the first 6 months after the screening.

The high prevalence of untreated CKD may indicate people's poor engagement with their health. Administrative efforts by health insurers are being made with the aim to improve healthy behaviors using, for example, health behavioural science; however, their focus is currently on increasing the number of examinees of AHC and not on ensuring a linkage between positive AHC results and medical management. Our study may support the importance of such linkage; therefore, developing an effective strategy is warranted.[23]

The prevalence of CKD found in this study was <6%, which was relatively low compared to the previously estimated global prevalence of CKD that is between 11% and 13%.[3]

Although the CKD definition is slightly different between the studies, we assume that the main cause was most likely to be our sample characteristics, which did not include an older population. Furthermore, we analyzed only data from participants whose baseline and follow-up CKD-related data were available, which would have resulted in our sample to be slightly healthier than the age adjusted general population (Supplementary Table 6).

1  
2  
3 We found that people are most likely to be undiagnosed when CKD is detected at an  
4 annual screening unless they are already under medication for diabetes or hypertension at  
5 the screening. The result is in concordance with that of a US study using both Medicare  
6 claims and research study measurements to define CKD.[24] It shows that individuals  
7 with CKD identified in claims had a more risky profile than those with CKD identified  
8 by study measurements.  
9

10  
11  
12 The strengths of our study include the use of a large longitudinal health data including  
13 self-reported information on lifestyle and blood/urine tests that were linked to the medical  
14 claims database and external information on the number of insureds for each enterprise.  
15 This allowed us to choose individuals with undiagnosed CKD and investigate if medical  
16 treatment is associated with their progression of kidney disease for three years accounting  
17 for their working environment.  
18

19  
20  
21 This study has several limitations that should be considered when interpreting the results.  
22 First, we identified physician visits for CKD treatment using the code of diagnoses that  
23 appeared on medical insurance claims, and we do not know what “medical treatment”  
24 was provided at the visit. Treatment strategies for CKD are diverse depending on  
25 individual situations that may include a variety of recommendations for lifestyle changes  
26 and/or medication to treat or prevent the different problems caused by CKD. We could  
27 not specify what element of physician visit was effective to prevent the progression of  
28 kidney disease. It may be worthwhile for future researches to investigate what element of  
29 treatment should be provided for protection of kidney function and how we can improve  
30 health seeking behaviors after CKD screening in the general population.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Second, our instrument variables were not sufficiently strong (F statistics <10.0); they  
4 explain only a small proportion of the variations of physician visits. Using IV has a  
5 potential to control for unmeasured confounders, but at least three important prerequisites  
6 must be fulfilled: 1) the relevance assumption: the instrument has a causal effect on the  
7 exposure; 2) the exclusion restriction: the instrument affects the outcome only through  
8 the exposure; and 3) the exchangeability assumption: the instrument does not share  
9 common causes with the outcome.[25] Observational studies often face a weak  
10 association between instrument and exposure, as observed in our data; therefore, careful  
11 scrutiny of the exchangeability and the exclusion restriction is needed. Although these  
12 requirements cannot be directly verified in the data, the exchangeability assumption is  
13 partially verifiable in the data using measured covariates; the measured covariates were  
14 rather balanced between the quintiles of different instruments (Supplementary Tables 2-  
15 4). We would like to argue that the exclusion restriction was also met, but we could not  
16 fully rule out the possibility of any direct effect of the instrument on outcome. On the  
17 other hand, as we observed a substantially high prevalence of renal progression among  
18 those who had been under medical treatment at the screening (30% compared to 15%  
19 among those undiagnosed), it is the nature of observational studies that estimations of  
20 effectiveness of any treatment are likely to be biased by unmeasured confounding. In  
21 addition, we obtained similar results even with different IVs, alternative outcomes, and  
22 restricted samples in the sensitivity analyses. Considering the above points, it may not be  
23 too overstated that the standard regression analyses favouring the untreated group was  
24 likely due to unobservable characteristics of the participants that influenced whether they  
25 received treatment.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Third, damaged kidney function was measured by urine reagent strips, not by improved  
4 albuminuria, because it is the standard procedure adopted in AHC. KDIGO guidelines  
5  
6 state that urine reagent strip results can be substituted when albuminuria measurements  
7  
8 are not available. However, urine albumin measurements can provide a more specific and  
9  
10 sensitive measure of changes in glomerular permeability than urinary total protein.  
11  
12

13  
14  
15 Fourth, a possible bias of population should be considered. Although our participants  
16  
17 belong to a specific social insurer of architects and engineers, which covers a range of  
18  
19 socioeconomic status hierarchies, we confirmed that they are only slightly healthier than  
20  
21 the age-adjusted general population of Japan. However, careful consideration is needed  
22  
23 when we apply our results to other countries.  
24  
25

## 26 27 28 **ACKNOWLEDGMENTS**

29  
30 We would like to thank Editage ([www.editage.jp](http://www.editage.jp)) for English language editing.  
31  
32

## 33 34 35 **FUNDING**

36  
37 This work is supported by the Japan Society for the Promotion of Science KAKENHI  
38  
39 (grant number: 16K19251). The funding sources had no involvement in conducting the  
40  
41 study.  
42  
43

## 44 45 **LICENCE FOR PUBLICATION**

46  
47 The Corresponding Author has the right to grant on behalf of all authors, and does grant  
48  
49 on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing  
50  
51 Group Ltd to permit this article (if accepted) to be published in JECH and any other  
52  
53 BMJPGJL products and sublicences such to use and exploit all subsidiary rights, as set out  
54  
55  
56  
57

1  
2  
3 in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence->  
4 forms).

### 5 6 7 **COMPETING INTEREST**

8  
9  
10 None declared.

### 11 12 13 14 **CONTRIBUTORSHIP**

15  
16 SF conceived the conception and design of the work. SF, TI and YS contributed the  
17 acquisition of data. YY did analysis, interpretation of data for the work and drafted the  
18 manuscript. All authors revised it critically for important intellectual content and gave  
19 final approval of the version to be published.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

- 1 Saran R, Robinson B, Abbott KC, *et al.* US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis* 2017;**69**:A7-A8.
- 2 Mills KT, Xu Y, Zhang W, *et al.* A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int* 2015;**88**:950-7.
- 3 Hill NR, Fatoba ST, Oke JL, *et al.* Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. *PLoS One* 2016;**11**:e0158765.
- 4 Eckardt KU, Coresh J, Devuyst O, *et al.* Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet* 2013;**382**:158-69.
- 5 Levey AS, de Jong PE, Coresh J, *et al.* The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011;**80**:17-28.
- 6 Fox CS, Matsushita K, Woodward M, *et al.* Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012;**380**:1662-73.
- 7 Levey AS, Andreoli SP, DuBose T, *et al.* Chronic kidney disease: common, harmful, and treatable--World Kidney Day 2007. *Clin J Am Soc Nephrol* 2007;**2**:401-5.
- 8 Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. *Pragmat Obs Res* 2016;**7**:21-32.
- 9 Simmonds R, Evans J, Feder G, *et al.* Understanding tensions and identifying clinician agreement on improvements to early-stage chronic kidney disease monitoring in

1  
2  
3 primary care: a qualitative study. *BMJ Open* 2016;**6**:e010337.

4  
5 10 van Dipten C, van Berkel S, de Grauw WJC, *et al.* General practitioners'  
6  
7 perspectives on management of early-stage chronic kidney disease: a focus group study.  
8  
9 *BMC Fam Pract* 2018;**19**:81.

10  
11 11 Hoerger TJ, Wittenborn JS, Segel JE, *et al.* A health policy model of CKD: 2. The  
12  
13 cost-effectiveness of microalbuminuria screening. *Am J Kidney Dis* 2010;**55**:463-73.

14  
15 12 Komenda P, Ferguson TW, Macdonald K, *et al.* Cost-effectiveness of primary  
16  
17 screening for CKD: a systematic review. *Am J Kidney Dis* 2014;**63**:789-97.

18  
19 13 Yarnoff BO, Hoerger TJ, Simpson SK, *et al.* The cost-effectiveness of using  
20  
21 chronic kidney disease risk scores to screen for early-stage chronic kidney disease. *BMC*  
22  
23 *Nephrol* 2017;**18**:85.

24  
25 14 Japanese Ministry of Health LaW. Specific Health Checkups and Specific Health  
26  
27 Guidance. *Annual Health, Labour and Welfare Report 2008-2009* 2010.

28  
29 15 KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of  
30  
31 Chronic Kidney Disease. *Kidney International Supplements* 2013.

32  
33 16 Horio M, Imai E, Yasuda Y, *et al.* Modification of the CKD epidemiology  
34  
35 collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.  
36  
37 *Am J Kidney Dis* 2010;**56**:32-8.

38  
39 17 Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular  
40  
41 filtration rate. *Ann Intern Med* 2009;**150**:604-12.

42  
43 18 Trojano M, Tintore M, Montalban X, *et al.* Treatment decisions in multiple  
44  
45 sclerosis - insights from real-world observational studies. *Nat Rev Neurol* 2017;**13**:105-18.

46  
47 19 Muto T, Higashi T, Mizoue T, *et al.* Multiple channels for occupational health  
48  
49



- 1  
2  
3 services to small-scale enterprises in Japan. *Occup Med (Lond)* 1995;**45**:268-72.
- 4  
5 20 Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing  
6  
7 endogeneity in health econometric modeling. *J Health Econ* 2008;**27**:531-43.
- 8  
9  
10 21 Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk  
11  
12 differences in Stata. *Stata Journal* 2013;**13**:492-509.
- 13  
14  
15 22 Fenger-Gron M, Kjaersgaard MIS, Parner ET, *et al.* Early treatment with talk  
16  
17 therapy or antidepressants in severely bereaved people and risk of suicidal behavior and  
18  
19 psychiatric illness: an instrumental variable analysis. *Clin Epidemiol* 2018;**10**:1013-26.
- 20  
21  
22 23 Fukuma S, Ikenoue T, Sasaki S, *et al.* Nudging patients with chronic kidney disease  
23  
24 at screening to visit physicians: A protocol of a pragmatic randomized controlled trial.  
25  
26 *Contemporary Clinical Trials Communications* 2019;**16**:100429.
- 27  
28  
29 24 Muntner P, Gutierrez OM, Zhao H, *et al.* Validation study of medicare claims to  
30  
31 identify older US adults with CKD using the Reasons for Geographic and Racial  
32  
33 Differences in Stroke (REGARDS) Study. *Am J Kidney Dis* 2015;**65**:249-58.
- 34  
35  
36 25 Lousdal ML. An introduction to instrumental variable assumptions, validation and  
37  
38 estimation. *Emerg Themes Epidemiol* 2018;**15**:1.
- 39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3  
4  
5 **Figure legend**  
6

7  
8 Cumulative probability of medical treatment depicted using the Kaplan-Meier plot of  
9  
10 time to visit a physician for chronic kidney disease (CKD) treatment after the indexed  
11  
12 annual health check-up (AHC) for 12 months.  
13  
14  
15  
16

17 **Abbreviations:** AHC, annual health check-up  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1



For Review Only

Supplementary Table 1 CKD-related diagnosis codes in ICD-10

	ICD-10_1 codes
Chronic kidney disease	N170, N171, N172, N178, N179, N180, N188, N189, N19, N990
Tubulo-interstitial nephritis	N110, N111, N118, N119, N12, N140, N141, N142, N143, N144, N150
Chronic glomerular nephritis	N002, N003, N004, N006, N007, N009, N012, N014, N016, N017, N019, N028, N029, N030, N032, N033, N034, N036, N037, N039, N040, N042, N044, N046, N049, N050, N051, N052, N053, N054, N055, N056, N057, N058, N059, N069, N079, N085
Diabetic nephropathy	E102, E112, E132, E142
Hypertensive nephrosclerosis	I129, I120
Polycystic kidney disease	Q613

CKD, chronic kidney disease; ICD-10, International Classification of Diseases, 10th revision

Supplementary Table 2 Baseline characteristics of cohort across categories of IV variable: size of enterprise

	<50	≥50, <300	≥300
Median of instrument (range)	26 (0-49)	125 (50-286)	2702 (300-10710)
Number of people	459	1131	2672
Medical treatment	1.53	2.56	2.32
Age (years)			
40-49	25.27	28.90	39.41
50-59	31.79	33.01	34.26
60-	42.93	38.08	26.33
Male	88.0	90.15	87.23
Proteinuria	62.40	64.64	66.50
eGFR (ml/min)			
<60	43.20	39.81	38.14
60-90	48.53	48.31	51.30
≥90	8.27	11.88	10.56
Systolic blood pressure ≥140 mmHg	35.47	33.87	23.79
Diastolic blood pressure ≥90 mmHg	26.93	27.53	23.75
HbA1c ≥6.5%	18.38	19.70	15.63
BMI			
<22.9	23.73	25.51	27.39
23-27.4	51.20	44.26	47.39
≥27.5	25.07	30.23	25.22
Antihypertensive drugs	39.73	39.41	31.80
Anti-diabetic drugs	12.53	13.23	11.14
Anti-hyperlipidemic drugs	16.53	19.57	18.65
History of cardiovascular disease/stroke	5.60	5.94	6.34
Smoking	40.53	37.38	29.90

IV, instrumental variable; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; BMI, body mass index

Supplementary Table 3 Baseline characteristics of cohort across quintiles of IV variable: proportion of AHC receivers

	1	2	3	4	5
Median of instrument (range)	14.9 (1.13-17.6)	21.3 (17.7-22.3)	23.4 (22.3 – 24.8)	26.2 (25.0-27.1)	31.2 (27.1-100)
Number of people	788	836	593	740	734
Medical Treatment	1.52	1.56	2.53	2.70	2.59
Age (years)					
40-49	37.02	38.35	41.13	32.24	31.40
50-59	35.75	34.47	30.55	33.06	34.30
60-	27.23	27.18	28.33	34.71	34.30
Male	84.14	85.65	92.07	88.38	91.14
Proteinuria	62.18	64.59	71.16	63.51	68.80
eGFR(ml/min)					
<60	41.37	40.07	32.71	41.76	37.33
60-90	49.71	48.56	54.81	49.59	51.23
>=90	9.39	11.36	12.48	8.65	11.44
Systolic Blood Pressure 140 $\leq$ mmHg	20.30	26.91	24.45	29.59	33.38
Diastolic Blood Pressure 90 $\leq$ mmHg	19.42	25.12	26.64	25.68	27.93
HbA1c 6.5 $\leq$ %	14.91	15.38	16.07	16.64	20.85
BMI					
<22.9	26.90	28.11	25.13	28.78	23.71
23-27.4	45.05	46.29	50.93	46.62	47.68
27.5 $\leq$	28.05	25.60	23.95	24.59	28.61
Antihypertensive drugs	34.90	34.57	30.35	33.11	37.06
Anti-diabetic drugs	12.06	9.33	10.46	12.03	14.85
Anti-hyperlipidemic drugs	17.89	18.78	15.35	21.08	19.35
History of cardiovascular disease/stroke	7.23	6.22	5.40	7.43	4.50
Smoking	30.58	31.34	33.22	30.41	37.33

IV, instrumental variable; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; BMI, body mass index

Supplementary Table 4 Baseline characteristics of cohort across quintiles of IV variable: observed/expected

	1	2	3	4	5
Median of instrument (range)	0.00 (0.00 to 0.24)	0.39 (0.24 to 0.50)	0.59 (0.50 – 0.68)	0.77 (0.68 to 0.83)	1.02 (0.83 to 51.6)
Number of people	741	743	826	668	723
Medical treatment	1.89	1.75	1.45	3.74	2.07
Age (years)					
40-49	27.73	40.84	40.79	37.20	32.35
50-59	33.47	35.14	34.15	32.23	33.61
≥60	38.80	24.02	25.06	30.57	34.04
Male	87.99	88.83	84.38	89.52	89.76
Proteinuria	62.21	66.62	64.53	68.41	67.22
eGFR (ml/min)					
<60	42.78	38.22	38.86	36.68	38.17
60-90	48.45	50.61	50.36	51.95	50.90
≥90	8.77	11.17	10.77	11.38	10.93
Systolic blood pressure ≥140 mmHg	33.47	24.90	22.88	26.65	27.52
Diastolic blood pressure ≥90 mmHg	26.32	25.17	23.61	24.55	24.62
HbA1c ≥6.5%	17.53	17.00	15.38	17.29	16.60
BMI					
<22.9	25.10	25.98	28.69	25.75	27.39
23-27.4	47.64	45.36	46.73	48.65	47.58
≥27.5	27.26	28.57	24.58	25.60	25.03
Antihypertensive drugs	37.79	32.71	30.87	34.88	34.85
Anti-diabetic drugs	13.50	10.77	10.63	12.72	11.07
Anti-hyperlipidemic drugs	16.87	17.63	18.40	21.71	18.81
History of cardiovascular disease/stroke	6.61	6.06	5.21	7.34	5.95
Smoking	36.57	28.13	28.45	35.78	34.30

IV, instrumental variable; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; BMI, body mass index

Supplementary Table 5 Sensitivity analyses

	Restricted sample to people with CKD confirmed through consecutive two years (n=1,181)				eGFR slope decline alternatively defined as 5 mL/min/1.73 m <sup>2</sup> /year or a greater		Alternative IV
	Treated within 6 months N=39	Left Untreated N=1,224	Age and sex adjusted RD <sup>†</sup> (95% CI)	Adjusted* RD <sup>†</sup> (95% CI)	IV Adjusted** RD <sup>†</sup> (95% CI)	IV Adjusted** RD <sup>†</sup> (95% CI)	IV Adjusted** RD <sup>†</sup> (95% CI)
Composite outcome	20.5 (9.3 to 36.5)	20.0 (17.8 to 22.4)	-1.11 (-12.76 to 12.53)	6.45 (-2.88 to 15.78)	21.47 (8.57 to 34.57)	8.80 (7.95 to 9.64)	16.27 (15.15 to 17.38) F=1.80
eGFR slope decline§	21.6 (9.8 to 38.2)	18.0 (15.8 to 20.4)	-3.29 (-16.55 to 9.97)	3.69 (-6.01 to 13.38)	19.98 (17.87 to 22.09)	6.63 (5.93 to 7.32)	14.88 (13.78 to 15.99)
Proteinuria incidence¶	0 (0.0 to 28.5)	9.8 (7.3 to 12.6)	-			10.39 (8.79 to 11.99)	10.35 (8.76 to 11.94)

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IV, instrumental variable; RD, risk difference; CI, confidence interval

\*Adjusted for gender, age (numeric), baseline eGFR (numeric), baseline proteinuria (binary), baseline body mass index (numeric), baseline diabetes mellitus (binary), baseline hypertension (binary), baseline smoking status (binary), history of stroke (binary), and history of cardiovascular disease (binary)

\*\*‡ Instrumental variable analysis via a two-stage residual inclusion approach using enterprise-level variables as instruments. Weak instrument was tested using the Montiel-Pflueger robust weak instrument test (confidence level alpha=0.05) with effective F statistics.

† Risk differences were estimated from logistic regression models with progression of kidney disease as a dependent variable with treated within 6 months as a reference. Positive values indicate a higher probability of progression of kidney disease for people left untreated.



Supplementary Table 6 Characteristics of the study population and the Japanese general population

	Study population		Age-standardized*	
	N=71,233		Japanese general population	
	Male	Female	Male	Female
	N=53,341	N=17,892		
Age categories, %				
40-49		49.3%		43.5%
50-59		33.4%		36.5%
60-65		17.2%		20.0%
Antidiabetic drugs, %	5.9 %	1.1 %	6.5%	2.7%
Antihypertensive drugs, %	18.2%	7.5 %	21.0%	12.0%
SBP, mean, mmHg	126.9	118.1	131.8	123.3
DBP, mean, mmHg	79.7	70.8	83.9	76.6
HbA1c, mean, %	5.6	5.5	5.7	5.6

SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c

\*Adjusted for the 2017 age-gender distribution of the Japanese population aged 40–64 years.


We extracted data from the online portal website for the official statistics of Japan

(<http://www.e-stat.go.jp/>).

## 2014 Annual Health Check-up (AHC)

## Medical claims

## 2015-2017 AHC



Supplement Fig.1 Selection process of the study participants and time points of measurement of the exposure and outcome variables